

HNF1 α upregulates the human AE2 anion exchanger gene (*SLC4A2*) from an alternate promoter

Raquel Malumbres,¹ Jon Lecanda,^{1,2} Saida Melero, Pawel Ciesielczyk, Jesús Prieto, and Juan F. Medina*

Laboratory of Molecular Genetics, Division of Hepatology and Gene Therapy, CIMA, University Clinic and Medical School, University of Navarra, E-31008 Pamplona, Spain

Received 8 September 2003

Abstract

The human AE2 gene (*SLC4A2*) is transcribed in a widespread fashion from the upstream promoter, the resultant full-length transcript AE2a being encountered in most tissues. Moreover, alternate promoter sequences within intron 2 may drive tissue-restricted expression of variants AE2b₁ and AE2b₂, mainly in liver and kidney. AE2b₂ proximal promoter sequences are highly active in transfected liver-derived HepG2 cells and contain an HNF1 motif. Mutation-disruption of this motif dramatically decreased alternate promoter activity in HepG2 cells but not in prostate-derived PC-3 cells. Electromobility shift and supershift assays indicated that HNF1 α from HepG2 nuclear extracts binds the HNF1 sequence. Transactivation studies in PC-3 cells showed enhanced activity of the wild-type construct upon cotransfection with an HNF1 α expression plasmid, while activity of the HNF1-mutated construct remained unaffected. Since liver AE2 is putatively involved in the biliary secretion of bicarbonate, HNF1 α may have a role in increasing bicarbonate secretion in response to certain stimuli.

© 2003 Elsevier Inc. All rights reserved.

Keywords: Human AE2; Alternate promoter; Chloride/bicarbonate exchange; Hepatocyte nuclear factor 1 α ; Liver-derived HepG2 cells; Prostate-derived PC-3 cells; Tissue-specific expression

Na⁺-independent anion exchangers (AE) are membrane proteins that mediate electroneutral and reversible exchange of Cl[−] and HCO₃[−] across the plasma membrane [1,2]. AE polypeptides usually load Cl[−] into the cell and extrude HCO₃[−], promoting intracellular acidification. In cooperation with other ion carriers, they are involved in the regulation of intracellular pH, cell volume homeostasis, and transepithelial acid/base transport. To date, four members of the AE family (AE1, AE2, AE3, and AE4) have been characterized in several species [2–5]. The corresponding genes show similarities in size, sequence, and exon/intron organization, although they are located in different chromosomes. A common feature among AE genes is the usage of alter-

native promoters, which lead to the expression of alternative transcripts, most often in a tissue-specific manner [1]. Thus, a 5′-truncated variant of the erythroid AE1 mRNA [6–9] is expressed in the kidney, while an AE3 transcript is found in cardiac muscle as a 5′-truncated variant of the complete form, which is mainly expressed in brain [10–13]. Concerning AE2, the complete message transcribed from the upstream promoter (AE2a) has been encountered in all human tissues that have been explored (liver, stomach, thyroid, prostate, and kidney), while expression of two 5′-truncated AE2 mRNAs (AE2b₁ and AE2b₂) was only found in liver and kidney [14]. Alternative exons 1b₁ and 1b₂ are transcribed from AE2b₂/AE2b₁ overlapping promoter sequences within intron 2 [14], each one splicing to exon 3 in corresponding 5′-truncated variants. As a result of the 5′-diversity of human AE2 mRNAs, the first 17 amino acids of AE2a are replaced by three initial residues (MTQ) in AE2b₁ and by eight initial residues (MDFLLRPQ) in AE2b₂. While former experiments

* Corresponding author. Fax: +34-948-42-57-00.

E-mail address: jfmedina@unav.es (J.F. Medina).

¹ These authors contributed equally to this work.

² Present address: Ruttenberg Cancer Center, NYU-Mount Sinai School of Medicine, New York, NY 10029, USA.

showed the capability of the AE2a message to be functionally expressed in human cells [15,16], recent experiments provide similar evidence for the alternative messages AE2b₁ and AE2b₂.

AE2 is the member of the AE family putatively involved in the biliary secretion of bicarbonate. Immunohistochemical studies in human liver using a monoclonal antibody against a peptide common to all three AE2 isoforms showed immunoreactivity at the luminal surface of the hepatobiliary tree only [17]. Therefore, it seems that all three AE2 isoforms have an apical location, each being able to participate in the secretion of bicarbonate to bile. In this context, the use of alternate promoter sequences may result in differentially regulated expression of AE2 isoforms in hepatobiliary cells. Previous dual-luciferase reporter gene assays of AE2b₂/AE2b₁ overlapping promoter regions in transiently transfected HepG2 cells determined that a 310-bp region corresponding to the proximal promoter of AE2b₂ is highly active [14]. This region contains several potential binding motifs for liver-enriched factors, including the sequence TCTTAATGATTAACC, which is a 1-bp variant (underlined) of the 15-bp consensus sequence for hepatocyte nuclear factor-1 (HNF1) [18]. There are two liver-enriched transcription factors, HNF1 α and HNF1 β , that may bind the HNF1 element as homo- or heterodimers [19–21]. Both HNF1 α and HNF1 β are expressed mainly in liver and kidney, but also in intestine and pancreas [22], while HNF1 β alone is found in lung and gonads [23,24]. Liver HNF1 α has been recently reported to be a master player in regulating bile acid and cholesterol metabolism [25,26].

Here, we determined that HNF1 α can: (i) bind the HNF1-motif variant of the human AE2 alternate promoter region and (ii) transactivate alternative transcription of the AE2 gene. Our findings suggest that HNF1 α may have a major role in upregulating alternative transcription of the human AE2 gene in the liver, and therefore it may contribute to the biliary secretion of bicarbonate in response to certain stimuli.

Materials and methods

Human cell lines. HepG2 cells (from human hepatoblastoma) were grown in DMEM with glutamax, while PC-3 cells (from human prostate cancer) were grown in RPMI 1640 with glutamax (Gibco). Both media were supplemented with 10% fetal calf serum (Gibco), penicillin/streptomycin (BioWhittaker), and 10 mM Hepes (Sigma), pH 7.4, at 37°C.

Isolation of total RNA and real-time polymerase chain reaction. Total RNA was isolated from each cell line with the TRI Reagent (Sigma). Reverse transcription of total RNA (2 μ g) and real-time polymerase chain reaction (PCR) were performed as described [27], using specific primers (Sigma-Genosys) (cf. Table 1 and Fig. 1).

Transient transfections with promoter–luciferase constructs. PCR fragments corresponding to alternate promoter sequences were obtained as described [14], using specific oligonucleotides (Table 2).

Table 1

Oligonucleotides used for the analysis of mRNA expressions by real-time PCR

Oligonucleotide	Sequence (5' to 3')
GAPDH forward	CCAAGGTCATCCATGACAAC
GAPDH reverse	TGTCATACCAGGAAATGAGC
AE2a forward	TCCAGAGCGAGCGGGTTATG
AE2b ₁ forward	CGCCCGCAGGATGACTCA
AE2b ₂ forward	CCCTCCTTCTCAGGTTACCCCTGCC
AE2 reverse (common for all isoforms)	GAGGACTGGCGGTGGTACTCAAAGTC
HNF1 α forward	TGGGTCCTACGTTACCAAC
HNF1 α reverse	TCTGCACAGGTGGCATGAGC
HNF1 β forward	TGCACAAAGCCTCAACACCT
HNF1 β reverse	GTTGGTGAGTGTACTGATGC




Fig. 1. Comparisons between HepG2 and PC-3 cells in the expression of mRNA isoforms for AE2 and HNF1. After reverse transcription of total RNA, expression of mRNA isoforms was measured by real-time PCR using specific primer pairs (cf. Table 1). Data were normalized with GAPDH. The levels of transcript expressions in PC-3 cells are given as percentage (means \pm SEM of at least three samples) of those in HepG2, which are each noted as 100%.

A promoter fragment with a 6-bp disrupted HNF1 motif was obtained through a PCR-based mutagenesis protocol [28] employing internal mutated oligonucleotides (Table 2). Promoter fragments were ligated to *Sma*I-linearized vector pGL3-basic (Promega), the integrity of each insert being further confirmed by sequence analysis. Transient transfections and assessments for luciferase activities with the Dual-Luciferase Reporter Assay System (Promega) were carried out as described [14], with minor modifications. Briefly, cells were seeded in 24-well culture plates (8×10^4 HepG2 cells/well or 4×10^4 PC-3 cells/well) one day before transfections. HepG2 cells were transfected by the calcium phosphate precipitation method [29], using for each well 0.2 μ g of the corresponding promoter construct, 1 ng of the internal standard pRL-SV40 construct, and 1.9 μ g of carrier DNA (vector pGL3 basic). PC-3 cells were transfected with 0.4 μ g of the corresponding promoter

Table 2
Oligonucleotides used for the production of promoter fragments by PCR

Oligonucleotide	Orientation	Sequence (5' to 3')
–471b ₂	Forward	CCTACCCTGACTTTGCATGA
–286b ₂	Forward	TAGAGGCGCAGGTCAAGTCT
+24b ₂	Reverse	TGAGGCCGCAGGAGGAAGTCCAT
–143b ₂	Reverse	CAAAGGGGGCCATGTGGAGC
Int-Mut-HNF1	Forward	<u>AGCGCCTC</u> ACGCCGTGCCACAATCAGCTCC
Int-Mut-HNF1	Reverse	GCGTGAGGCGCTAAGACTCCTTAGGAAAATC

Oligonucleotide name indicates the position of each oligonucleotide 5'-end in the promoter sequence referred to the corresponding start codon. The last two are internal oligonucleotides used in the mutagenesis procedure (underlined nucleotides indicate mutations that disrupted the HNF1 element).

construct and 2 ng of pRL-SV40 per well, using the Tfx-50 Reagent (Promega). For cotransfection assays with PC-3 cells, 0.2 µg per well of either pBJ5-HNF1α or the empty vector pBJ5 (kindly provided by Dr. Gerald Crabtree [30]) was added to the transfection reaction. Forty-two hours after transfections, dual-luciferase activities were assayed in a Lumat LB 9507 luminometer (EG&G Berthold).

Preparation of nuclear extracts and electromobility shift assays. HepG2 or PC-3 cells seeded in 150 × 20 mm culture plates (TPP) were grown until 70–80% confluence and collected with a Costar cell scraper. Cell centrifugation and following steps to recover the nuclear proteins were all performed at 4°C. The cellular pellet was resuspended in a lysis buffer (10 mM Hepes, pH 7.9, 1.5 mM MgCl₂, 10 mM KCl, 1 mM DTT from Sigma, and 1× Complete Protease Inhibitor Cocktail Tablets from Roche). After 15-min incubation, cells were homogenized and nuclei were pelleted (12,000g for 1 min). The pellet was resuspended in appropriate buffer (20 mM Hepes, pH 7.9, 25% glycerol, 1.5 mM MgCl₂, 420 mM NaCl, 0.2 mM EDTA, 1 mM DTT, and protease inhibitor as above) and incubated for 30 min, with brief vortexing every 5 min. Nuclear membranes were pelleted (12,000g for 5 min) and the supernatant was dialyzed for 2 h at 4°C against 50 ml of a dialysis buffer (20 mM Hepes, pH 7.9, 20% glycerol, 100 mM KCl, 0.2 mM EDTA, 1 mM DTT, and protease inhibitor). Following centrifugation at 13,000g for 5 min, the supernatant was stored at –80°C. Nuclear extracts from PC-3 cells transfected with either the expression vector pBJ5-HNF1α or the empty vector pBJ5 were also prepared; 150 × 20 mm culture plates were seeded with 7.2 × 10⁵ cells, each plate being transfected the following day with 36 µg of corresponding vector using Tfx-50 Reagent (Promega). Forty-two hours after transfection nuclear proteins were extracted as described above. Protein concentrations were measured by using the Bradford method (Bio-Rad).

For electromobility shift assays (EMSAs), the double-stranded probe 5'-CCTAAGGAGTCTTAATGATTAACCCCGTGCC-3' (HNF1 motif underlined) was produced by annealing of partially complementary oligonucleotides HNF1 forward and HNF1 reverse (Table 3), followed by 3'-end filling with Klenow (New-England Biolabs). Unincorporated nucleotides were removed with a Nick Column (Amersham) and digoxigenin-11-ddUTP was incorporated to each 3'-end using the Dig Gel Shift Kit (Roche). Mutated probe was generated with oligonucleotides mutated-HNF1 forward and mutated-HNF1 reverse

(Table 3), containing the same changes as the promoter construct with a disrupted HNF1 motif; cf. above). Each probe (0.2 pmol) was incubated in a 20-µl mixture with 1 µg of poly(dI-dC) (Amersham), 8–16 µg of nuclear extract from non-transfected cells, 12 mM Hepes, pH 7.8, 0.1 M KCl, 1 mM EDTA, 1 mM DTT, 5% glycerol, and 50 ng BSA. For competition assays, an excess of unlabeled probe (1-, 10- or 30-fold) was added. As non-specific DNA-binding competitor an unlabeled probe with an Oct2A-binding site was used. Supershift experiments included the addition of 4 µg of anti-HNF1α or anti-HNF1β antibodies (Supershift reagent sc-6548 X or sc-7411 X, respectively, Santa Cruz Biotechnology). Binding reactions were incubated for 15 min at room temperature before electrophoresis on a 4% polyacrylamide gel. After electrotransference to a positively charged nylon membrane (Roche), bands were detected non-isotopically with the Dig Gel Shift Kit and exposed to an autoradiography film for at least 30 min.

When using nuclear extracts from PC-3 transfected cells, a lower amount was prepared and isotopic EMSA was performed to increase the sensitivity. The HNF1 probe was labeled with [³²P]ATP (Amersham) and T4 polynucleotide kinase (Promega). Binding buffer and conditions were the same as for non-isotopic EMSA, but only 0.02 pmol of probe and 2 µg of nuclear extract were used. After PAGE, the gel was dried and exposed to an autoradiography film for at least 42 h.

Western blot. Eight micrograms of nuclear extracts in 66 mM Tris, 100 mM DTT, 2.6% SDS, 4.8 M urea, 10% glycerol, and 10 mg/ml of bromophenol blue was run in 0.1% SDS–6% PAGE and electrotransferred to a Biotrace NT membrane (Pall). Sequential incubations were carried out with anti-HNF1α (sc-6548 X diluted 1/8000) and anti-goat IgG-HRP (a donkey antibody from Santa Cruz Biotechnology, diluted 1/100,000). Western Lightning (Perkin-Elmer) and *Hyperfilm ECL* (Amersham) were used for visualization of the bands.

Results

Comparative studies between HepG2 and PC-3 cells for the expression of AE2 and HNF1 mRNA isoforms

Real-time quantitative PCR showed that the steady-state levels of AE2a mRNA were higher (144 ± 18%) in prostate-derived PC-3 cells than in liver-derived HepG2 cells, whereas the levels of both alternative messages AE2b₁ and AE2b₂ were significantly lower (14 ± 2% and 18 ± 2%, respectively) in prostate cells (Fig. 1). The low expression of alternative transcripts in PC-3 cells was associated with low levels of HNF1 transcripts in these cells compared to HepG2 cells. In fact, expression of HNF1α mRNA was undetectable in prostate cells and the levels of HNF1β mRNA were significantly lower (23 ± 1%) in these cells than in HepG2 (Fig. 1).

Table 3
Oligonucleotides used for the production of HNF1 probes for EMSA

Oligonucleotide	Sequence (5' to 3')
HNF1 forward	CCTAAGGAGTCTTAATGATTAACCCCG
HNF1 reverse	GGCACGGGGTTAATCATTAAGACTC
Mutated-HNF1 forward	CCTAAGGAGTCTTA <u>AGCGCCT</u> ACGCGC
Mutated-HNF1 reverse	GGCACGGG <u>CGTGAGGCGCT</u> AAGACTC

Underlined nucleotides indicate mutations that disrupt the HNF1 binding site.

Involvement of the HNF1 motif in the alternate transcriptional activity of AE2

We assessed the functionality of the 1-bp variant of the HNF1 consensus sequence spanning positions $-127b_2$ to $-113b_2$ in the minimal AE2 b_2 promoter [14]. Thus, we carried out transfections of HepG2 cells with promoter constructs either lacking the region with the HNF1 sequence (see the 3'-deleted construct $-286b_2/-143b_2$ in Fig. 2) or containing a disrupted HNF1 motif with six mutations of the consensus sequence ($-286b_2/+24b_{2Mut}$). Dual-luciferase assays with transfected HepG2 cells showed that transcriptional activities were markedly attenuated versus cells transfected with the wild-type construct $-286b_2/+24b_2$ ($28 \pm 1\%$ and $32 \pm 3\%$, respectively; both $p < 0.001$, cf. Fig. 2). In PC-3 cells, luciferase activities were much lower (approximately 50-fold) than in HepG2 cells. In PC-3 cells, however, HNF1-motif disruption in $-286b_2/+24b_{2Mut}$ had no effect ($101 \pm 9\%$ versus wild-type construct $-286b_2/+24b_2$; data not shown), indicating that the HNF1 motif is not functional in these cells.

Binding of HNF1 α to the HNF1 motif

EMSA with HepG2 nuclear extracts and a DIG-labeled 31-bp probe containing the HNF1 sequence (and flanking bases in the promoter) resulted in two shifted bands (Fig. 3A). Only the upper shifted band was

specific, since it could be competed with unlabeled specific probe, but not with an unlabeled probe having a disrupted HNF1 motif or with the non-specific oligonucleotide Oct2A (Fig. 3A). Furthermore, the upper shifted band was not obtained when performing EMSAs with the labeled probe containing the disrupted version of the HNF1 site (Fig. 3B). These data show that our 1-bp variant of the HNF1 element is able to bind nuclear proteins from HepG2 extracts. Interestingly, EMSA using a labeled probe with the C at the second nucleotide (the 1-bp variant of the HNF1 consensus sequence) mutated to G (the consensus nucleotide) showed a similar binding than the wild-type HNF1 probe (Fig. 3B).

When supershift assays with antibodies to HNF1 α and HNF1 β were carried, a supershift of the specific shifted band was only observed with the HNF1 α antibody but not with the HNF1 β antibody (Fig. 3C). Therefore, in HepG2 cells the HNF1 element appears to be bound by HNF1 α /HNF1 α homodimers.

No specific shifted band was detected in EMSA with PC-3 nuclear extracts instead of HepG2 extracts (Fig. 4A). This was expected because HNF1 α is not expressed in PC-3 cells, as indicated by real-time PCR experiments (Fig. 1). Western blot performed with nuclear extracts confirmed that HNF1 α is present in HepG2 but not in PC-3 cells (Fig. 4B). On the other hand, immunoblot analysis of PC-3 cells transfected with an HNF1 α -expressing vector showed expression of




Fig. 2. Luciferase activities of constructs with sequences of the human alternate overlapping promoters AE2 b_2 /AE2 b_1 . The upper diagram shows the promoter regions from the distal part of intron 1 to the end of exon 1b₁. Dual-luciferase assays of HepG2 cells transiently transfected with the corresponding constructs were carried out in triplicate and repeated several times (indicated by the numbers inside the bars). For each experiment, relative luciferase units were normalized with values obtained for the reference construct $-286b_2/+24b_2$; results are given as means \pm SEM. Statistical significance (*) of differences to the reference construct was determined by Student's t test with the Bonferroni correction ($\alpha = 0.01$). Black arrows indicate the location of the HNF1 motif; \times indicates the mutagenesis-disrupted HNF1 site.




Fig. 3. HNF1α transcription factor from HepG2 nuclear extract is able to bind to the HNF1 element. (A) EMSA using nuclear extracts from HepG2 cells and competition assays with several oligonucleotides, i.e., unlabeled HNF1 oligonucleotide, mutated oligonucleotide with a disrupted HNF1 site, and oligonucleotide with an Oct2A element. Each competitor was assayed at 1, 10 or 30 molar excess with respect to the labeled probe. (B) EMSA with mutated labeled probes: using a probe with the HNF1 element disrupted by a 6-bp mutation resulted in no specific shifted band; experiments using an HNF1 probe with the C at the second nucleotide mutated to G (the consensus nucleotide) showed a similar binding than the wild-type HNF1 probe. (C) Supershift experiments carried out with antibodies to HNF1α and HNF1β indicate that HNF1α is binding to the HNF1 element. All these EMSAs were performed non-isotopically with digoxigenin-labeled probes.

HNF1α in these cells (Fig. 4B). EMSA and supershift studies using nuclear extracts from PC-3 cells transfected with the HNF1α vector demonstrated the occurrence of HNF1α binding activity in these transfected cells (Fig. 4C).

Transactivation studies in PC-3 cells

To demonstrate that HNF1α may transactivate the human alternate AE2 promoter, wild-type construct -286b₂/+24b₂ and the HNF1-mutated counterpart -286b₂/+24b₂Mut (Fig. 2) were each cotransfected with either the pBJ5-HNF1α vector or the empty vector pBJ5 into PC-3 cells (Fig. 5), which do not express HNF1α (cf. Figs. 1 and 4B). Luciferase activity of cells transfected with the wild-type construct was markedly increased when cotransfected with the expression vector for HNF1α (231 ± 18%, $p < 0.001$; see Fig. 5), whereas no increase was observed in cells cotransfected with the empty vector pBJ5 (96 ± 9%, not significant). On the other hand, the




Fig. 4. Transfection with an HNF1α vector and expression of HNF1α in PC3 cells. (A) In contrast to the experiments with nuclear extract from HepG2 cells, EMSA with nuclear extract from PC-3 cells does not show the upper shifted band due to HNF1α; this EMSA was performed non-isotopically with a digoxigenin-labeled probe. (B) Western blot for the immunodetection of HNF1α in nuclear extracts from HepG2 and PC-3 cell lines: while HNF1α is present in HepG2 cells, this transcription factor is not detected in PC-3 cells prior to their transfection; transfection with pBJ5-HNF1α induces the appearance of HNF1α in the nucleus of PC-3 cells. (C) EMSA using nuclear extracts prepared from PC-3 cells transfected with pBJ5-HNF1α; a major shifted band equivalent to that observed when using nuclear extracts from HepG2 cells was supershifted with the anti-HNF1α antibody. This EMSA was performed using a ³²P-labeled probe.




Fig. 5. Cotransfection with an HNF1α-expressing vector transactivates the wild-type AE2b₂ proximal promoter in PC3 cells. Dual-luciferase assays using PC-3 cells cotransfected with the expression vector pBJ5-HNF1α or the empty vector pBJ5 and either the wild-type (wt) HNF1 containing construct -286b₂/+24b₂ or its mutated (mut) version in construct -286b₂/+24b₂Mut, were carried out in triplicate and repeated at least nine times. Values are all given as percentage of the reference construct -286b₂/+24b₂. Mean values are represented and the error bars are the standard error of the mean. Statistical significance (*) of differences was determined by Student's *t* test with the Bonferroni correction ($\alpha = 0.01$).

activity of mutated construct $-286b_2/+24b_{2Mut}$ was not affected by any cotransfection, remaining similar to that of the wild-type construct transfected alone into PC-3 cells ($109 \pm 10\%$ and $108 \pm 10\%$ for pBJ5 and pBJ5-HNF1 α cotransfections, respectively, both not significant; Fig. 5). Thus, cotransfection experiments in PC-3 cells demonstrate that HNF1 α is able to transactivate the AE2 b_2 proximal promoter.

Discussion

The human AE2 anion exchanger gene is widely expressed from its upstream promoter AE2a. In the liver as well as in the kidney, this gene may also be alternatively expressed from overlapping promoter sequences AE2 b_2 /AE2 b_1 within intron 2 [14]. In the present study, we have determined that liver-enriched nuclear factor HNF1 α plays an important role for transactivating the alternate promoter AE2 b_2 in liver-derived HepG2 cells, and that HNF1 α exerts this function through its binding to the HNF1 motif in the alternate promoter AE2 b_2 [14]. Moreover, our data from real-time PCR and luciferase studies show that this is not the case in prostate-derived cell line PC-3, and indicate that HNF1 α -mediated alternative transcription of the AE2 gene in humans is rather cell specific, similar to what has been recently reported in rabbit gastric mucosa for the different cell types [31].

The HNF1 motif located at position $-113b_2$ in the overlapping alternate promoter sequences AE2 b_2 /AE2 b_1 follows the most stringent criteria reported for bona fide HNF1 sites [18]. Thus, it locates in the minimal AE2 b_2 promoter region and is particularly surrounded by other transcription factor motifs [14]. However, our HNF1 motif contains a C at the second nucleotide position in the consensus sequence that, to our knowledge, has never been found among hundreds of them [18]. EMSA experiments showed that nuclear extract from HepG2 cells binds similarly either HNF1-probes with C or G at the second nucleotide position (Fig. 3B).

The HNF1 element is known to be able to interact with homo- or heterodimers of HNF1 α and HNF1 β [19–21]. They both are factors included in the wide HNF network [32,33] that may regulate tissue-restricted expression of some genes [34–40]. Hypothetically, either HNF1 α and/or HNF1 β could be responsible for the transcriptional activation of the AE2 alternate promoter in liver-derived HepG2 cells. However, supershift assays indicate that the HNF1 element is mainly bound by HNF1 α /HNF1 α homodimers in these liver cells (Fig. 3C). In prostate cells, the lack of HNF1 α binding activity (Fig. 4A) correlates well with the absence of HNF1 α expression in these cells (Figs. 1 and 4B). PC-3 cells transfected with an HNF1 α vector to express

HNF1 α (Fig. 4B) showed HNF1 α binding activity as determined by EMSA and supershift studies (Fig. 4C). Cotransfection experiments in these prostate cells definitely demonstrated that HNF1 α can transactivate the AE2 b_2 proximal promoter (Fig. 5). These experiments also suggest that cell-specific alternative AE2 expression is largely influenced by the presence or absence of HNF1 α , although other transcription factors are most probably involved as well. Thus, cells lacking HNF1 α , such as PC-3, show low but detectable expression of alternative transcripts (Fig. 1), and disruption of the HNF1 motif does not fully eliminate transcriptional activity of the AE2 b_2 proximal promoter in any of the two cell lines tested.

Former studies have demonstrated that, in basal conditions, expression of alternative messages AE2 b_1 and AE2 b_2 accounts each for about 10% of the full-length AE2a expression [14], which is driven from upstream promoter sequences that resemble house-keeping gene promoters [41]. The physiological significance of an alternative expression of the AE2 gene in the liver regulated by HNF1 α might be related to the possibility for liver cells to increase the expression of the AE2 gene when needed for bicarbonate secretion. Biliary secretion of bicarbonate occurs through a Na⁺-independent anion exchange along the apical membrane of hepatobiliary cells. All three AE2 isoforms may be involved in this exchange, as recent studies in HEK293 cells transfected with AE2-isoform-expressing vectors indicate that each isoform is able to display AE activity at a similar degree (V. Aranda, S.M., and J.F.M., unpublished).

The role of HNF1 α in directing the expression of genes involved in bile acid transport has been recently highlighted. The livers of Hnf1 α (*Tcf1*) knockout mice show decreased expression of several basolateral membrane bile acid transporter genes such as *Slc10a1* (*Ntcp* or sodium taurocholate cotransporting polypeptide gene), *Slc21a3* (*Oatp1* or organic anion transporting polypeptide-1 gene), and *Slc21a5* (*Oatp2*), leading to impaired portal bile acid uptake [25]. Moreover, the promoter regions of *Oatp4* and its human ortholog *OATP-C* have been shown to be responsive to HNF1 α [42]. These and other studies [26,43,44] provide support for an important role of HNF1 α as a key regulator of liver-specific organic anion transporter genes and hence for the production of the bile acid-dependent bile flow. Likewise, our present report provides evidence that HNF1 α is able to regulate a gene involved in biliary secretion of bicarbonate, and thus in the generation of the bile acid-independent bile flow.

Acknowledgments

We are grateful to E. Sáez for excellent technical assistance, A. Izal, J. M. Bañales, Drs. M. Zaratiegui, and R. Hernández for their help,

and J. Salas, Drs. C.D. Funk, and F. Lecanda for valuable advice on the manuscript. Also, we thank Dr. G. Crabtree for kindly providing pBJ5 vectors. This work was supported by grants from the Spanish Fondo de Investigaciones Sanitarias (Project 99/0647) and from the Instituto de Salud Carlos III (C03/02), and by the FIMA foundation. R. Malumbres was a recipient of a predoctoral fellowship from the Spanish Ministry of Education and Science.

References

- [1] S.L. Alper, The band 3-related AE anion exchanger gene family, *Cell. Physiol. Biochem.* 4 (1994) 265–281.
- [2] S.L. Alper, R.B. Darman, M.N. Chernova, N.K. Dahl, The AE gene family of $\text{Cl}^-/\text{HCO}_3^-$ exchangers, *J. Nephrol.* 15 (Suppl. 5) (2002) S41–S53.
- [3] H. Tsuganezawa, K. Kobayashi, M. Iyori, T. Araki, A. Koizumi, S. Watanabe, A. Kaneko, T. Fukao, T. Monkawa, T. Yoshida, D.K. Kim, Y. Kanai, H. Endou, M. Hayashi, T. Saruta, A new member of the HCO_3^- transporter superfamily is an apical anion exchanger of β -intercalated cells in the kidney, *J. Biol. Chem.* 276 (2001) 8180–8189.
- [4] M.D. Parker, E.P. Ourmozdi, M.J.A. Tanner, Human BTR1, a new bicarbonate transporter superfamily member and human AE4 from kidney, *Biochem. Biophys. Res. Commun.* 282 (2001) 1103–1109.
- [5] L. Lipovich, E.D. Lynch, M.K. Lee, M.C. King, A novel sodium bicarbonate cotransporter-like gene in an ancient duplicated region: SLC4A9 at 5q31, *Genome Biol.* 2 (2001) RESEARCH0011. Epub 2001, Mar 22.
- [6] F.C. Brosius III, S.L. Alper, A.M. Garcia, H.F. Lodish, The major kidney band 3 gene transcript predicts an amino-terminal truncated band 3 polypeptide, *J. Biol. Chem.* 264 (1989) 7784–7787.
- [7] A. Kollert-Jöns, S. Wagner, S. Hubner, H. Appelhans, D. Drenckhahn, Anion exchanger 1 in human kidney and oncocytoma differs from erythroid AE1 in its NH_2 terminus, *Am. J. Physiol.* 265 (1993) F813–F821.
- [8] K.E. Sahr, W.M. Taylor, B.P. Daniels, H.L. Rubin, P. Jarolim, The structure and organization of the human erythroid anion exchanger (AE1) gene, *Genomics* 24 (1994) 491–501.
- [9] A.E. Schofield, P.G. Martin, D. Spillett, M.J. Tanner, The structure of the human red blood cell anion exchanger (EPB3, AE1, band 3) gene, *Blood* 84 (1994) 2000–2012.
- [10] S.C. Linn, K.E. Kudrycki, G.E. Shull, The predicted translation product of a cardiac AE3 mRNA contains an N terminus distinct from that of the brain AE3 $\text{Cl}^-/\text{HCO}_3^-$ exchanger. Cloning of a cardiac AE3 cDNA, organization of the AE3 gene, and identification of an alternative transcription initiation site, *J. Biol. Chem.* 267 (1992) 7927–7935.
- [11] C.W. Morgans, R.R. Kopito, Generation of truncated brain AE3 isoforms by alternate mRNA processing, *J. Cell Sci.* 106 (1993) 1275–1282.
- [12] D. Yannoukakos, A. Stuart-Tilley, H.A. Fernández, P. Fey, G. Duyk, S.L. Alper, Molecular cloning, expression, and chromosomal localization of two isoforms of the AE3 anion exchanger from human heart, *Circ. Res.* 75 (1994) 603–614.
- [13] S.C. Linn, G.R. Askew, A.G. Menon, G.E. Shull, Conservation of an AE3 $\text{Cl}^-/\text{HCO}_3^-$ exchanger cardiac-specific exon and promoter region and AE3 mRNA expression patterns in murine and human hearts, *Circ. Res.* 76 (1995) 584–591.
- [14] J.F. Medina, J. Lecanda, A. Acín, P. Ciesielczyk, J. Prieto, Tissue-specific N-terminal isoforms from overlapping alternate promoters of the human AE2 anion exchanger gene, *Biochem. Biophys. Res. Commun.* 267 (2000) 228–235.
- [15] B.S. Lee, R.B. Gunn, R.R. Kopito, Functional differences among nonerythroid anion exchangers expressed in a transfected human cell line, *J. Biol. Chem.* 266 (1991) 11448–11454.
- [16] D. Sterling, J.R. Casey, Transport activity of AE3 chloride/bicarbonate anion-exchange proteins and their regulation by intracellular pH, *Biochem. J.* 344 (1999) 221–229.
- [17] E. Martínez-Ansó, J.E. Castillo, J. Díez, J.F. Medina, J. Prieto, Immunohistochemical detection of chloride/bicarbonate anion exchangers in human liver, *Hepatology* 19 (1994) 1400–1406.
- [18] F. Tronche, F. Ringeisen, M. Blumenfeld, M. Yaniv, M. Pontoglio, Analysis of the distribution of binding sites for a tissue-specific transcription factor in the vertebrate genome, *J. Mol. Biol.* 266 (1997) 231–245.
- [19] S. Baumhueter, D.B. Mendel, P.B. Conley, C.J. Kuo, C. Turk, M.K. Graves, C.A. Edwards, G. Courtois, G.R. Crabtree, HNF-1 shares three sequence motifs with the POU domain proteins and is identical to LF-B1 and APF, *Genes Dev.* 4 (1990) 372–379.
- [20] D.B. Mendel, L.P. Hansen, M.K. Graves, P.B. Conley, G.R. Crabtree, HNF-1 α and HNF-1 β (vHNF-1) share dimerization and homeo domains, but not activation domains, and form heterodimers in vitro, *Genes Dev.* 5 (1991) 1042–1056.
- [21] E. Ktistaki, I. Talianidis, Modulation of hepatic gene expression by hepatocyte nuclear factor 1, *Science* 277 (1997) 109–112.
- [22] S. Cereghini, Liver-enriched transcription factors and hepatocyte differentiation, *FASEB J.* 10 (1996) 267–282.
- [23] V. De Simone, R. Cortese, Transcription factors and liver-specific genes, *Biochim. Biophys. Acta* 1132 (1992) 119–126.
- [24] M. Reber, S. Cereghini, Variant hepatocyte nuclear factor 1 expression in the mouse genital tract, *Mech. Dev.* 100 (2001) 75–78.
- [25] D.Q. Shih, M. Bussen, E. Sehayeck, M. Ananthanarayanan, B.L. Schneider, F.J. Suchy, S. Shefer, J.S. Bollilini, F.J. Gonzalez, J.L. Breslow, M. Stoffel, Hepatocyte nuclear factor-1 α is an essential regulator of bile acid and plasma cholesterol metabolism, *Nat. Genet.* 27 (2001) 375–382.
- [26] D. Jung, G.A. Kullak-Ublick, Hepatocyte nuclear factor 1 α : a key mediator of the effect of bile acids on gene expression, *Hepatology* 37 (2003) 622–631.
- [27] S. Melero, C. Spirli, A. Zsembery, J.F. Medina, R.E. Joplin, E. Duner, M. Zuin, J.M. Neuberger, J. Prieto, M. Strazzabosco, Defective regulation of cholangiocyte $\text{Cl}^-/\text{HCO}_3^-$ and Na^+/H^+ exchanger activities in primary biliary cirrhosis, *Hepatology* 35 (2002) 1513–1521.
- [28] B. Cormack, Directed mutagenesis using the polymerase chain reaction: introduction of point mutations by sequential PCR steps, in: F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.C. Seidman, J.A. Smith, K. Struhl (Eds.), *Current Protocols in Molecular Biology*, Wiley, New York, 1997, pp. 8.5.7–8.5.10.
- [29] F.L. Graham, A.J. van der Eb, A new technique for the assay of infectivity of human adenovirus 5' DNA, *Virology* 52 (1973) 456–467.
- [30] G. Courtois, S. Baumhueter, G.R. Crabtree, Purified hepatocyte nuclear factor 1 interacts with a family of hepatocyte-specific promoters, *Proc. Natl. Acad. Sci. USA* 85 (1988) 7937–7941.
- [31] H. Rossmann, O. Bachmann, Z. Wang, G.E. Shull, B. Obermaier, A. Stuart-Tilley, S.L. Alper, U. Seidler, Differential expression and regulation of AE2 anion exchanger subtypes in rabbit parietal and mucous cells, *J. Physiol.* 534 (2001) 837–848.
- [32] S.A. Duncan, M.A. Navas, D. Dufort, J. Rossant, M. Stoffel, Regulation of a transcription factor network required for differentiation and metabolism, *Science* 281 (1998) 692–695.
- [33] Y. Hayashi, W. Wang, T. Ninomiya, H. Nagano, K. Ohta, H. Itoh, Liver enriched transcription factors and differentiation of hepatocellular carcinoma, *Mol. Pathol.* 52 (1999) 19–24.
- [34] A. Aguanno, R. Afar, V.R. Albert, Tissue-specific expression of the nonneuronal promoter of the aromatic L-amino acid decar-

- boxylase gene is regulated by hepatocyte nuclear factor 1, *J. Biol. Chem.* 271 (1996) 4528–4538.
- [35] J.A. Hochman, D. Sciaky, T.L. Whitaker, J.A. Hawkins, M.B. Cohen, Hepatocyte nuclear factor-1 α regulates transcription of the guanylin gene, *Am. J. Physiol.* 273 (1997) G833–G841.
- [36] R.H. Erickson, J.R. Gum, C.D. Lotterman, J.W. Hicks, R.S. Lai, Y.S. Kim, Regulation of the gene for human dipeptidyl peptidase IV by hepatocyte nuclear factor 1 α , *Biochem. J.* 338 (1999) 91–97.
- [37] C. Hu, D.H. Perlmutter, Regulation of α 1-antitrypsin gene expression in human intestinal epithelial cell line Caco-2 by HNF-1 α and HNF-4, *Am. J. Physiol.* 276 (1999) G1181–G1194.
- [38] K. Okita, Q. Yang, K. Yamagata, K.A. Hangenfeldt, J. Miyagawa, Y. Kajimoto, H. Nakajima, M. Namba, C.B. Wollheim, T. Hanafusa, Y. Matsuzawa, Human insulin gene is a target gene of hepatocyte nuclear factor-1 α (HNF-1 α) and HNF-1 β , *Biochem. Biophys. Res. Commun.* 263 (1999) 566–569.
- [39] M.G. Martin, J. Wang, R.S. Solorzano-Vargas, J.T. Lam, E. Turk, E.M. Wright, Regulation of the human Na⁺-glucose cotransporter gene, *SGLT1*, by HNF-1 and Sp1, *Am. J. Physiol.* 278 (2000) G591–G603.
- [40] F. Boudreau, Y. Zhu, P.G. Traber, Sucrase-isomaltase gene transcription requires the HNF-1 regulatory element and is regulated by the ratio of HNF-1 α to HNF-1 β , *J. Biol. Chem.* 276 (2001) 32122–32128.
- [41] J.F. Medina, A. Acín, J. Prieto, Molecular cloning and characterization of the human AE2 anion exchanger (*SLC4A2*) gene, *Genomics* 39 (1997) 74–85.
- [42] D. Jung, B. Hagenbuch, L. Gresh, M. Pontoglio, P.J. Meier, G.A. Kullak-Ublick, Characterization of the human OATP-C (*SLC21A6*) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 α , *J. Biol. Chem.* 276 (2001) 37206–37214.
- [43] S.J. Karpen, A.Q. Sun, B. Kudish, B. Hagenbuch, P.J. Meier, M. Ananthanarayanan, F.J. Suchy, Multiple factors regulate the rat liver basolateral sodium-dependent bile acid cotransporter gene promoter, *J. Biol. Chem.* 271 (1996) 15211–15221.
- [44] M. Trauner, M. Arrese, H. Lee, J.L. Boyer, S.J. Karpen, Endotoxin downregulates rat hepatic *ntcp* gene expression via decreased activity of critical transcription factors, *J. Clin. Invest.* 101 (1998) 2092–2100.